Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2850065rdf:typepubmed:Citationlld:pubmed
pubmed-article:2850065lifeskim:mentionsumls-concept:C1882598lld:lifeskim
pubmed-article:2850065lifeskim:mentionsumls-concept:C0079883lld:lifeskim
pubmed-article:2850065lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:2850065lifeskim:mentionsumls-concept:C0231491lld:lifeskim
pubmed-article:2850065lifeskim:mentionsumls-concept:C1510827lld:lifeskim
pubmed-article:2850065lifeskim:mentionsumls-concept:C1707127lld:lifeskim
pubmed-article:2850065lifeskim:mentionsumls-concept:C0439282lld:lifeskim
pubmed-article:2850065lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:2850065lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:2850065lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:2850065pubmed:issue3lld:pubmed
pubmed-article:2850065pubmed:dateCreated1989-2-16lld:pubmed
pubmed-article:2850065pubmed:abstractText1. CGS 19755 (cis-4-phosphonomethyl-2-piperidine carboxylic acid), a rigid analogue of 2-amino-5-phosphonopentanoic acid (AP5), is one of the most potent competitive N-methyl-D-aspartate (NMDA) antagonists described. Using Triton-treated crude synaptic membranes from rat brain, binding studies indicated that [3H]-CGS 19755 bound with high affinity and selectivity to the NMDA-type excitatory amino acid receptor. 2. [3H]-CGS 19755 binding was saturable, reversible, heat-labile, pH-dependent and linear with protein concentration. Specific binding represented 80-85% of the total amount bound. 3. Using a centrifugation assay, saturation experiments revealed two distinct binding components with Kd values of 9 and 200 nM, and corresponding Bmax values of 0.55 and 1.00 pmol mg-1 protein. In contrast, a single binding component with a Kd value of 24 nM and an apparent Bmax value of 0.74 pmol mg-1 protein was observed with a filtration assay. 4. Competition experiments in which both assay techniques were used, showed that [3H]-CGS 19755 selectively labels the NMDA receptor. The most active inhibitors of [3H]-CGS 19755 binding were L-glutamate and CGS 19755 (IC50 values = 100 nM). 5. In the centrifugation assay, a number of excitatory amino acids were found to generate shallow inhibition curves, and computer analysis indicated the presence of two binding components. The quisqualate receptor ligand AMPA (D,L-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate), kainic acid and the non-competitive NMDA antagonists, such as phencyclidine, tiletamine and MK-801, were without activity. 6. The high affinity binding obtained with [3H]-CGS 19755 by use of filtration techniques thus permits the more rapid evaluation of compounds as potential NMDA antagonists and agonists. Therefore, this rigid analogue of AP5 is a more suitable radioligand for NMDA receptors than [3H]-CPP (34-+/-)2-carboxypiperazin-4-yl)propyl-1-phosphonic acid), the corresponding analogue of 2-amino-7-phosphonoheptanoic acid (AP7).lld:pubmed
pubmed-article:2850065pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2850065pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2850065pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2850065pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2850065pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2850065pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2850065pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2850065pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2850065pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2850065pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2850065pubmed:languageenglld:pubmed
pubmed-article:2850065pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2850065pubmed:citationSubsetIMlld:pubmed
pubmed-article:2850065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2850065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2850065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2850065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2850065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2850065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2850065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2850065pubmed:statusMEDLINElld:pubmed
pubmed-article:2850065pubmed:monthNovlld:pubmed
pubmed-article:2850065pubmed:issn0007-1188lld:pubmed
pubmed-article:2850065pubmed:authorpubmed-author:WilliamsMMlld:pubmed
pubmed-article:2850065pubmed:authorpubmed-author:KlunBBlld:pubmed
pubmed-article:2850065pubmed:authorpubmed-author:SillsM AMAlld:pubmed
pubmed-article:2850065pubmed:authorpubmed-author:HutchisonA...lld:pubmed
pubmed-article:2850065pubmed:authorpubmed-author:MurphyD EDElld:pubmed
pubmed-article:2850065pubmed:issnTypePrintlld:pubmed
pubmed-article:2850065pubmed:volume95lld:pubmed
pubmed-article:2850065pubmed:ownerNLMlld:pubmed
pubmed-article:2850065pubmed:authorsCompleteYlld:pubmed
pubmed-article:2850065pubmed:pagination932-8lld:pubmed
pubmed-article:2850065pubmed:dateRevised2010-4-23lld:pubmed
pubmed-article:2850065pubmed:meshHeadingpubmed-meshheading:2850065-...lld:pubmed
pubmed-article:2850065pubmed:meshHeadingpubmed-meshheading:2850065-...lld:pubmed
pubmed-article:2850065pubmed:meshHeadingpubmed-meshheading:2850065-...lld:pubmed
pubmed-article:2850065pubmed:meshHeadingpubmed-meshheading:2850065-...lld:pubmed
pubmed-article:2850065pubmed:meshHeadingpubmed-meshheading:2850065-...lld:pubmed
pubmed-article:2850065pubmed:meshHeadingpubmed-meshheading:2850065-...lld:pubmed
pubmed-article:2850065pubmed:meshHeadingpubmed-meshheading:2850065-...lld:pubmed
pubmed-article:2850065pubmed:meshHeadingpubmed-meshheading:2850065-...lld:pubmed
pubmed-article:2850065pubmed:meshHeadingpubmed-meshheading:2850065-...lld:pubmed
pubmed-article:2850065pubmed:meshHeadingpubmed-meshheading:2850065-...lld:pubmed
pubmed-article:2850065pubmed:meshHeadingpubmed-meshheading:2850065-...lld:pubmed
pubmed-article:2850065pubmed:meshHeadingpubmed-meshheading:2850065-...lld:pubmed
pubmed-article:2850065pubmed:meshHeadingpubmed-meshheading:2850065-...lld:pubmed
pubmed-article:2850065pubmed:year1988lld:pubmed
pubmed-article:2850065pubmed:articleTitleCharacterization of the binding of [3H]-CGS 19755: a novel N-methyl-D-aspartate antagonist with nanomolar affinity in rat brain.lld:pubmed
pubmed-article:2850065pubmed:affiliationResearch Department, CIBA-GEIGY Corporation, Summit, NJ 07901.lld:pubmed
pubmed-article:2850065pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2850065lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2850065lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2850065lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2850065lld:pubmed